troglitazone has been researched along with Joint Diseases in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Joint Diseases: Diseases involving the JOINTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Whereas high dosage of full agonists may expose RA patients to cardiovascular adverse effects, the proof of concept that PPAR agonists have therapeutical relevance to OA may benefit from an epidemiological follow-up of joint lesions in diabetic or hyperlipidemic patients treated for long periods of time with glitazones or fibrates." | 2.44 | [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists]. ( Bianchi, A; Jouzeau, JY; Koufany, M; Moulin, D; Netter, P; Sebillaud, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jouzeau, JY | 1 |
| Moulin, D | 1 |
| Koufany, M | 1 |
| Sebillaud, S | 1 |
| Bianchi, A | 1 |
| Netter, P | 1 |
1 review available for troglitazone and Joint Diseases
| Article | Year |
|---|---|
[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
Topics: Animals; Arthritis, Rheumatoid; Chromans; Dimerization; Extracellular Matrix; Humans; Hypoglycemic A | 2008 |